Almac Partners with Merck KGaA and the MRC to Assess Markers of Response to Cetuximab Therapy
News Apr 12, 2010
Almac, Merck KGaA, Darmstadt, Germany, and the Medical Research Council (MRC), a UK-based, publicly-funded organization to improving human health, have entered into a partnership to undertake a study in metastatic colorectal cancer (mCRC) using samples from the MRC COIN trial. The aim of the study is to assess potential biomarkers of response to cetuximab (Erbitux®).
The value of biomarkers in optimizing treatment outcomes has already been recognized. The American Society of Clinical Oncology (ASCO) acknowledged in 2008 the use of the KRAS as a predictive biomarker for cetuximab in newly diagnosed advanced colon cancer as a “major research advance” that will “help guide treatment for each patient, increasing efficacy while eliminating unnecessary adverse effects in those who will not benefit from the treatment.”
This personalized treatment approach was also recognized by regulatory bodies such as the European Medicines Agency (EMA) which approved cetuximab in combination with standard chemotherapy as a 1st-line treatment for mCRC in patients with KRAS wildtype tumors.
Almac will utilize samples from the COIN trial to carry out quantitative polymerase chain reaction profiling and data analysis to assess other potential biomarkers in the context of combination therapy with cetuximab.
Prof. Tim Maughan, Director, Wales Cancer Trials Unit, explained, “The MRC COIN trial is the largest trial of therapy in patients with advanced colorectal cancer and tested the addition of cetuximab to oxaliplatin based chemotherapy regimen. This collaboration will enable us to identify whether biomarkers apart from the Kras status alone further define which patients may benefit most from the addition of cetuximab to chemotherapy.”
Prof. Paul Harkin, president of Almac Diagnostics, said; “Almac are delighted to once again be involved in such an important study. The use of retrospective analysis from formalin fixed paraffin embedded samples will be one of the keys to successfully delivering better molecular diagnostics, which is paramount in the development of personalized medicine.”
The MRC COIN study is a phase III, multicentre, three arm study in 1st-line treatment of mCRC. The study focuses on examining whether the combination of oxaliplatin and cetuximab with fluoropyrimidine chemotherapy improves patient outcomes.
Low Temperatures Turn Stem Cells into Calorie-Burning FatNews
The secret to healthy eating may not be in freezer food, but low temperatures can help turn stem cells into brown fat, a type of fat which helps burn calories. A new study could turn this knowledge into weight-loss treatments.READ MORE
Comments | 0 ADD COMMENT
11th International Conference and Exhibition on Metabolomics & Systems Biology
May 17 - May 19, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018